Last Price
6.13
Today's Change
-0.17 (2.69%)
Day's Change
6.11 - 6.48
Trading Volume
885,598
Market Cap
1 Billion
Shares Outstanding
311 Million
Avg Volume
1,478,484
Avg Price (50 Days)
5.18
Avg Price (200 Days)
2.98
PE Ratio
-51.08
EPS
-0.12
Earnings Announcement
21-Aug-2024
Previous Close
6.30
Open
6.32
Day's Range
6.11 - 6.48
Year Range
0.88 - 6.5
Trading Volume
885,598
1 Day Change
-2.70%
5 Day Change
1.49%
1 Month Change
20.43%
3 Month Change
142.29%
6 Month Change
161.97%
Ytd Change
191.90%
1 Year Change
590.91%
3 Year Change
308.67%
5 Year Change
308.67%
10 Year Change
308.67%
Max Change
308.67%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.